Introduction
Melanoma is a prevalent, aggressive form of cancer in dogs. New treatment or preventive modalities are necessary to control this disease in dogs. On December 03, 2020, the Brazilian Association of Veterinary Oncology, ABROVET, organized the “Colloquium on Canine Melanoma” to present the newest achievements for the treatment of this disease.
Invited talks included fundamental aspects of canine melanoma, and conventional and innovative therapies. The talks were delivered online and more than 100 attendees joined the transmission. This report aims to present the most important information about canine melanoma discussed at the Colloquium.
Canine Melanoma: Fundamental Aspects
Melanocytic Neoplasms in Dogs: A Pandora's Box, by Carlos Eduardo Fonseca Alves
Canine oral melanoma is one of the most diffuse tumors in dogs worldwide and it is related to a high metastatic rate and poor prognosis. The first publication regarding melanocytic tumors was in 1949 (), and the first publication of a canine melanoma from oral mucosa was in 1950 (). After the publication of the first oral melanoma case report (), several other studies have been performed in order to establish diagnostic, prognostic, and predictive markers.
The first important approach for treating dogs with oral melanoma is to establish the prognosis (). Although several studies have tried to standardize new prognostic molecular factors, the histological features remain pivotal. Recently, the Oncology Pathology Working Group (OPWG), a Veterinary Cancer Society and American College of Veterinary Pathologists initiative, proposed a consensus on the diagnosis of and histopathologic prognostication for canine melanocytic neoplasms (). Among the histological prognostication criteria proposed in the consensus, nuclear atypia, vascular invasion, and mitotic index were considered in addition to other histological criteria (Figure 1). Interestingly, the degree of pigmentation presented a direct relation with overall survival. Thus, dogs with amelanotic melanoma had a shorter lifespan (). However, the outcome is not predictable in melanomas with moderate, low, or no pigmentation ().
Figure 1
Owing to the increasing use of big data in cancer research, recent studies have focused on different molecular prognostic and predictive markers for canine oral melanoma. Among them, somatic focal amplifications on chromosome 30 have been associated with poor patient outcomes. Chromosomal imbalances and transcriptome dysregulations seem to be frequent in canine oral melanoma (–). To summarize genomic data associated with melanoma mutations, an integrative in silico analysis was performed with the two previous canine oral melanoma studies () and the human data available for human melanoma in “The Cancer Genome Atlas” (). This analysis identified 60 commonly mutated genes among human and canine melanomas (Figure 2).
Figure 2
Most of the 60 dysregulated genes were related to immune response and tyrosine kinase terms, such as negative regulation of T-helper cell differentiation, SCF complex assembly, and activation of protein kinase A activity. For a better visualization, the biological process terms related with the 60 genes are shown in Figure 3 (, ).
Figure 3
Among the 60 dysregulated genes in canine and human melanoma, protein-to-protein interaction (PPI) analysis was performed for better visualization of the protein interaction network. In this analysis, the disconnected nodes were excluded, which revealed four independent networks (Figure 4). The genes RPL8, POLR2B, FBXO32, and SOCS5 showed the highest interactions. RPL8 gene is a ribosomal protein responsible for protein synthesis and POLR2B is responsible for encoding the second largest subunit of RNA polymerase II. The FBXO32 gene is related to mediation of ubiquitination and degradation of target proteins and SOCS5 belongs to the suppressor of cytokine signaling family, recognized as a STAT inhibitor protein family (). This analysis identified genes that could be related to both canine and human melanomas.
Figure 4
Although canine oral melanoma has been studied for the past 70 years, the improvement of genomic and transcriptome analysis in the recent years allow for identification of markers that can be used with predictive or prognostic value.
Histological Aspects and Molecular Markers Associated With Aggressiveness in Melanomas, by Enio Ferreira
Regardless of the animal species affected, melanomas (malignant neoplasms of melanocytes) are aggressive neoplasms because of their high metastatic potential. In dogs, melanomas represent ~7% of all malignant tumors (). The most common primary sites are the oral cavity, skin, mucocutaneous junctions, paws (nail junction and cushions), and, more rarely, the eyeball and meninges (). Histopathological evaluation of melanomas can assist in both: the differential diagnosis of benign lesions and the prognostic determination. The mitotic index, nuclear atypia, and the degree of pigmentation stand out as relevant prognostic markers for melanomas. In addition to these, analysis of vascular invasion, junctional activity, and ulceration are also cited as determining prognostic factors in both cutaneous and oral melanomas by some authors (, ). There is no evidence that the histological type may be a relevant prognostic factor. The use of molecular markers (MELAN-A, PNL-2, HMB45, TRP-1, and TRP-2) is suggested for assisting the diagnosis of amelanotic melanomas, as these proteins are expressed in most of such tumors. Moreover, the analysis of Ki-67 expression is decisive in the prognostic definition of melanomas, but its analysis is dependent on the primary site of involvement (). The expression of COX-2, KIT, metalloproteinases, EGFR, SOX, and proteins related to the epithelium-mesenchymal transition has been well-explored in canine melanomas (–). These proteins have a direct relationship with a more aggressive histological behavior, determined by the histopathological characteristics mentioned above. The analysis of gene mutations in melanomas in veterinary medicine is still not well-understood. Some changes have already been identified in the NRAS gene, PTEN KIT, and ERK1/2; however, their relevance is still uncertain (). Clinical studies are necessary to determine the prognostic and predictive value of protein expressions and mutations in canine melanomas.
Conventional Therapies for Canine Melanoma
Oncological Surgery and Its Limitations on the Treatment of Melanoma in Dogs, by Jorge Castro
Surgery is the gold standard of treatment and the most common one for the local management of all melanomas, including oral (), cutaneous, and digital melanomas (). Surgical resection with wide margins has always been one of the recommended approaches for oral melanoma in dogs, associated with regional lymphadenectomy. The more aggressive resections involving the maxillary bone (maxillectomies) can be associated with temporary ligation of the carotid artery. This is an adjuvant surgical technique that the literature contemplates as a surgical option with a lower loss of blood. Although surgical treatment is the main choice, Liptak and Withrow () and Boston et al. () recommend that because of its high metastatic potential, systemic therapy should also be considered as a therapeutic option for melanomas.
Surgical resections with wide margins, including 2–3 cm of bone margins and 1 cm of soft tissue margins, were performed in 70 cases of canine oral malignant melanomas (). Histopathological analysis showed that 72.9% of the tumors were completely excised, with 10% of these patients showing local tumor recurrence. In this study, dogs that had surgery as the only treatment option had a progression-free interval >567 days and a mean survival time (MST) of 874 days. In the same year, Boston et al. () obtained 79.3% (73/92) success rate in complete excisions between surgeries performed with wide margin, based on histological evaluation, and the recurrence rate was 8.3% (6/73) in this group (). The average survival time for these dogs was 354 days.
The resection of regional lymph node neoplasms in the face and maxilla region has been studied and performed since the last century () and a more recent study has mapped these lymphatic centers (). The analysis of sentinel lymph nodes provides essential information about the clinical stage of the disease and helps to determine the most appropriate treatment plan (, ). In a survey conducted by Williams and Packer with 100 dogs with oral malignant melanoma, 53% had cytological or histopathological evidence of metastasis in mandibular lymph nodes, even in normal-sized lymph nodes (). Therefore, lymphatic toilet (removal of regional lymph nodes) is recommended, especially in dogs with oral melanomas. In digital melanomas, lymphatic drainage in the limbs must also be evaluated and the removal of the regional lymph node in surgical planning is advocated (, ).
Radiation Therapy in Dogs With Oral Melanomas, by Simone C. S. Cunha; Natália Oyafuso Da Cruz
Radiation therapy (RT) is a localized cancer treatment modality, which acts on proliferating cells that fall inside the radiation field. In cases of canine oral melanoma, RT can be used as an adjuvant post-operative or a palliative therapy. Radiation field should, whenever possible, include regional lymph nodes, regardless of whether they have macroscopic alterations suggestive of regional metastasis. The main radiation protocols for melanoma are based on hypofractionation (3–6 RT fractions once or twice weekly), due the alpha/beta ratio range of 0.5–2.5 Gy. These ratios are similar to those of late-responding normal tissues, which are preferentially damaged by radiation delivered in large doses per fraction (, ). Side effects are usually mild, self- limiting, and confined to radiation field, and may include alopecia, skin hypo- or hyperpigmentation, dry radiodermatitis, and oral mucositis. The overall response rate of oral melanoma in previous literature is reported to be 75–85%, including complete and partial tumor responses, and the mean survival time is 230–363 days (–). In the first author's (SCSC) experience, radiation therapy is routinely used as an adjunctive post-operative therapy (in cases of incomplete surgical resection) or, more commonly, as a palliative treatment (in unresectable tumors or surgery declined by the dog owners). The high rate of distant metastasis (44–58%) remains the significant limiting factor for curative intention treatment of canine oral melanoma (, , ). The author Cunha et al. () evaluated the survival of 24 dogs with oral melanoma treated with orthovoltage radiotherapy. The mean age and standard deviation was 13 ± 2.6 years and the overall response rate was 93%, including 64% partial (one stage I, one stage II, seven stage III, and one stage IV) and 29% complete tumor responses (one stage III and three stage IV). Mean survival time was 390 days in stage I, 286 days in stage II, 159 days in stage III, and 90 days in stage IV. There was no influence of sex and age in RT responses. In conclusion, Radiation Therapy can be an interesting alternative treatment for canine oral melanoma, leading to reduction of tumor volume and pain relief, with mild side effects.
Innovative Therapies for Canine Melanoma
Viral Vectors in Melanoma, by Bryan Strauss
Currently, immunotherapy has emerged as the most successful usage of viral vectors applied for gene therapy of melanoma, including IMLYGIC and chimeric antigen receptor T cells (CAR-T cells) (, ). In either case, the goal of the gene transfer approach clearly involves oncolysis (therapeutic destruction of tumor cells) associated with or due to the activity of immune cells. The work of the Viral Vector Laboratory (Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo) shares this objective and has developed a non-replicating adenoviral vector, AdRGD-PG, with improved mechanisms of transduction because of the inclusion of the RGD peptide in the virus fiber protein and high-level transcription of the therapeutic genes under the command of a p53-responsive promoter, termed PG (, ). Since melanoma cells frequently retain wild-type p53 (), this can be exploited to drive transgene expression and act as a tumor suppressor protein, when re-activated ().
We used the AdRGD-PG platform for the transfer of p14ARF (alternate reading frame of the CDKN2a locus, p19Arf in mice, p14ARF in humans, and canines) to activate p53 and promote cell death. In addition, transfer of the interferon-β gene not only acts as an immune modulator, but also contributes to the activation of p53 (). We used the B16F10 mouse model of melanoma to show that the combination of p19Arf and IFNβ gene transfer resulted in cooperative cell killing in vitro accompanied by the expression of immunogenic cell death (ICD) markers and in vivo where C57BL/6 mice revealed activation of a Th1 immune response (–). However, IFNβ is known to function in a species-specific manner (, ); therefore, it is imperative to test our approach in relevant models. Recent work using human cDNAs and established human melanoma cell lines produced a similar result, where cell killing was even more efficient and continued to be associated with the expression of ICD markers (, ). Strikingly, an ex vivo model using human SK-MEL-147 cells was used to show that cell death induced by our treatment activated human dendritic cells that caused priming of T cells to induce a cytolytic response on encountering naïve tumor cells (). Thus, we have shown that our gene transfer approach promotes oncolysis and immune activation and can be considered as an immunotherapy. Currently, we are gearing up to examine the efficacy of our approach in veterinary cases of melanoma because of their relevance and similarity to human cases as well as the demand for efficient therapies for canines. For this, a set of AdRGD-PG vectors has been constructed encoding the canine cDNAs of p14ARF and IFNβ. In parallel, three cell lines were isolated from canine oral melanomas (unpublished results), characterized for their ability to grow in tissue culture as well as form subcutaneous tumors in BALB/c nude mice. These cell lines were shown to harbor wild-type p53 and show permissive transduction and reporter gene expression with our AdRGD-PG vectors (). This model system is currently being tested and will serve as proof of concept before embarking on experimentation in spontaneous cases of canine oral melanoma. These critical steps have been taken to demonstrate the potential of our immunotherapy in a relevant model.
Immuno-Oncology in Canine Oral Melanoma, by Cristina De Oliveira Massoco
In the last 20 years, immunotherapy has gained prominence since this therapeutic modality has significantly increased the effectiveness of treatments and the survival rates of cancer patients. The discovery that cells of the immune system interact with tumor cells and eliminate them is not a totally new concept and was born in the middle of the nineteenth century with the experiments carried out by Coley on human patients (52). Several clinical observations about spontaneous tumor regression and evidence showing a positive correlation between the presence of lymphocyte in a tumor microenvironment and increased survival rate reveal an increasing interest in the cancer immunosurveillance theory.
Especially for malignant melanoma, control of the disease with classical therapies and clinical management remains challenging, and yet immunotherapy modalities seem to be promising. Such strategies include DNA-based canine melanoma vaccine, immunotherapy methods using dendritic cells, and (non) viral vectors to deliver gene products, among others that have been studied (53). Even though responding melanoma-bearing dogs may have a partial or complete regression, some patients who are treated with immunotherapy showed varying response rates within cohorts with the same malignancy (54). Studies have shown that the efficacy of the immune system, in an anti-tumor context, is limited by the characteristics of immune cells present in the tumor microenvironment. These are reprogrammed to an immunosuppressive profile determined mainly by tumor cells, thus generating fewer effective responses against tumors (55, 56).
Cancer cells actively employ various tactics to delay, alter, or even stop antitumor immunity. These mechanisms develop continuously during the progression of cancer and become more diverse and complex in late-stage cancers (57). Therefore, it is critical to identify tumor immunity in the microenvironment to determine the outcomes and responses to immunotherapy. Identifying specific defects in the antitumor immune response as infiltrated immune cell population analysis associated with other immune signatures in dogs could serve as a basis for future studies to choose patients who will benefit from immunotherapy for oral melanoma.
Immunotherapy in the Treatment of Patients With Melanoma: OncoTherad® Nano-Immunotherapy, by Wagner Fávaro
Canine oral melanoma (COM) is a highly aggressive and metastatic cancer. Many studies have demonstrated that post-treatment medium survival time ranges from 4.8 to 12 months (58). Conventional treatments have not shown suitable disease control partly because surgery rarely achieves complete resection, and chemotherapies require low tumor loads to be effective. Immunotherapy has become a promising cancer therapy, improving the prognosis of patients with many different types of cancer, and offering the possibility for long-term cancer remission. In this scenario, a new perspective is represented by OncoTherad® nano-immunotherapy. OncoTherad® is a nanostructured inorganic phosphate complex associated to glycosidic protein, developed by University of Campinas (UNICAMP), Brazil, which exhibits immunomodulatory and antitumor properties (59). OncoTherad® leads to a distinct stimulation of the innate immune system mediated by Toll-like receptors (TLRs) 2 and 4, resulting in an increased activation of the interferon (IFN) signaling pathway (60, 61). OncoTherad®-induced stimulation of the immune system via TLR2 and TLR4 occurs through the phosphorylation of hydroxylated amino acids, such as tyrosine, threonine, and serine by compounds that contain phosphate salts; this results in the activation of stimulator of interferon genes, with a consequent increase in the production of IFN-α and IFN-γ (62). The increase in the production of IFNs mediated by TLRs-2 and 4 promotes the activation of TCD8+ cells, dendritic cells, natural killer cells, and M1 macrophages, culminating in the induction of immunogenic cell death (62). Furthermore, OncoTherad® decreases the expression of receptor activator of nuclear factor-κB (RANK) and receptor activator of nuclear factor-κB ligand (RANK-L) system and, as a result, prevents or inhibits metastases progression (63). Thus, the aim of this study was to evaluate the efficacy of OncoTherad® nano-immunotherapy for first-line chemotherapy-relapse high-grade COM (with or without metastasis). We carried out a prospective, multicenter study in 19 (8 men, 11 women) consecutive patients with COM-relapse (≥1 previous course of first-line chemotherapy). OncoTherad® treatment (G1 group, n = 10) was initiated with its intramuscular (22 mg/mL) application twice per week for 3 months, followed by application, once every other week, until 1 year of treatment (Figure 5). OncoTherad® was associated (G2 group, n = 09) with chemotherapy (Carboplatin: 250—300 mg/m2—intravenous) or electrochemotherapy (bleomycin: 15,000 IU/m2—intravenous) (Figure 5). All canine patients received follow-up exams for 2 years. The Ethics Committee for Animal Experimentation (CEUA)/UNICAMP approved the animal procedures (protocol number 4861-1/2018). The median age of the 19 patients was 12.5 years (range 09–16) and follow-up time was 24 months. Based on iRECIST criteria, the overall complete response rate was 31.6% (G1 group−40.0%; G2 group−22.2%), overall partial response rate was 42.1% (G1 group−30.0%; G2 group−55.6%), and overall stable disease rate was 10.5% (G1 group−20.0%; G2 group−0.0%). Only 15.8% of total patients (G1 group−10.0%; G2 group−22.2%) presented progressive disease. The median overall progression-free survival was 640 days (G1 group−676.5 days, G2 group−599.4 days). In conclusion, OncoTherad® nano-immunotherapy seems an effective treatment option for chemotherapy-relapse COM patients and may provide benefits for preventing tumor progression.
Figure 5
Electrochemotherapy in the Treatment of Melanomas, by Marcelo Monte Mór Rangel
Electrochemotherapy is a new modality of local cancer treatment, which is increasingly gaining space, both in human and veterinary medicine. Its high index of objective response to different histological types, and its selectivity to cancerous tissue has encouraged its application in neoplasms that are more resistant to standard treatments. The main objective of surgery in the treatment of melanomas is the complete resection of the tumor and this usually occurs in wide surgeries. Large surgeries can be challenging in oral cavity melanomas and the need for adjuvant therapies aiming at better local control may be necessary. Electrochemotherapy is a local control technique with a high rate of objective response, selectivity to neoplastic tissue. Its use has been proposed in oral malignant melanomas that are difficult to resect, either as an adjunct to surgery or as a single treatment. The prior studies have shown promising results with singular use of the technique and its use as an adjunct with other therapies. These results corroborate the need for further studies to prove that the technique can be an alternative treatment for malignant melanomas in dogs (64–80).
Electrochemotherapy in the Treatment of Canine Oral Malignant mela noma, by Carlos Brunner
From July to December 2018, 58 melanomas in dogs were treated with electrochemotherapy with bleomycin and electroporation with BK100 electoporator, at the Universidade Paulista, UNIP, in São Paulo, SP, Brazil. The samples were composed as follows: a total of 54% of them were males, with an average age of 11.4 years. There was a higher prevalence of the following breeds: Yorkshire (10.7%), Golden Retriever (8.9%), Poodle (7.4%), Teckel (5.3%), and SRD (5.3%), similar to data found in literature. The incidence of oral melanomas was higher (75%), which was in contrast to the results of the literature review (62%). Bleomycin was used intra-lesionally at a dose of 1 U/cm3 or intravenously at a dose of 15 Y/m2, followed by electroporation with a BK100 pulse generator with a series of 8 pulses of 1 KV in 100 μs square waves each. This protocol has resulted in satisfactory survival rates after 2 years, including some complete remissions, in grade 1 and 2 melanomas. As described in classic literature, the anatomical location influences the biological behavior of melanomas; patients who underwent multimodal therapy, including surgery, conventional chemotherapy, and electrochemotherapy were the ones who obtained the best results.
Electrochemotherapy for the Treatment of Canine Melanoma: the Experience of Argentina, by Matías Tellado
For this round table, two cases of melanoma were presented. The results were evaluated according to the prognostic factors reported in previous work (81). The first patient was an 8-year-old, male cross-bred (mongrel) dog with stage I oral malignant melanoma located in the soft palate. No bone involvement was seen as determined by computed tomography scan. It was treated with BIOTEX EPV-200 (BIOTEX SRL, Buenos Aires, Argentina) electroporator, using 20 G disposable needles electrode. The device delivered 8,100 μs long square pulses of 1,000 V/cm at 5 kHz according to ESOPE 2018 standards (82). A month after the electrochemotherapy session, a complete response was obtained, and the patient remained disease free 11 months later and until the writing of this work. The second case was a 9 year-old female boxer with a stage IV oral malignant melanoma located in the right angle of the mandible, that extended to the soft palate and mucosa. No bone involvement was seen as assessed by CT scan. The patient had a small single pulmonary metastasis determined by chest radiograph. The treatment consisted of surgical excision of the oral mass, followed by ECT in the tumoral bed and margins. A month after the ECT treatment, the patient presented a complete local response. The local response and the lung metastasis remained unchanged until 5 months later. The results obtained were in accordance with previous published results regarding predictive factors of response to ECT in oral melanoma (80, 81). Early stages and absence of bone involvement displayed good response rates. In the second case, even if it was in an advanced stage, the combination with surgery to reduce the tumoral burden and the absence of bone involvement allowed us to expect a good outcome of the treatment.
Clinical Reports of Melanoma Undergoing Electrochemotherapy or Calcium Electroporation, by Denner Santos Dos Anjos
Multimodal therapies have been used in melanomas, such as surgery, radiotherapy, chemotherapy, immunotherapy, electrochemotherapy, and electro gene therapy. ECT is an effective local treatment that combines the administration of chemotherapeutic drugs, such as bleomycin or cisplatin, followed by the delivery of permeabilizing electrical pulses. In veterinary medicine, electrochemotherapy has been widely used because of its high efficacy in all solid tumors, such as cutaneous and subcutaneous tumors, skin metastasis, melanoma, sarcomas, and visceral tumors, such as thymoma and bladder cancer (83–89). In addition to bleomycin and cisplatin being the chemotherapeutic drugs mainly used in electrical pulses, carboplatin may also be a good candidate for electric pulses based on our clinical experience (Dr. Denner dos Anjos). Moreover, calcium electroporation (CaEP) is a novel therapeutic perspective for patients with cutaneous metastasis of MM and remission of metastatic melanoma foci. Its approach leads to supraphysiological calcium influx into neoplastic cells leading to acute ATP depletion killing cancer cells by necrosis and release of dangerous cellular signals boosting immunologic system locally. We have observed some patients diagnosed with MM stage III (tumor size more than 4 cm, negative lymph node) who underwent ECT with carboplatin plus CaEP had a disease free-interval of >720 days after one session or ECT with carboplatin and locally administered cisplatin (1 m/cm3) had a disease free-interval of >365 days. Furthermore, neoadjuvant ECT can also be used for partial remission in order to perform a better surgical approach for patients with advanced disease. To conclude, ECT may be an option for local control in regions where anatomic limitation is a challenge for wide excision.
Discussion and Conclusion
The goal of scientific meetings and workshops is to call attention to new achievements in the field to ensure advancement of science and applications. In conclusion, this colloquium provided important information about canine melanomas. The Brazilian Association of Veterinary Oncology, ABROVET, hopes that this report can help veterinary oncologists from all over the world to better diagnose and treat these aggressive neoplasms in dogs.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author’s note
The Brazilian Association of Veterinary Oncology, ABROVET, is a non-profit organization that was created in 2004 by veterinary oncologists from Brazil (https://abrovet.org.br/). ABROVET frequently organizes scientific and cultural events and seeks to develop the field of Veterinary Oncology in Brazil. In 2016, ABROVET organized the 3rd. World Veterinary Cancer Congress in the city of Foz do Iguaçu, Brazil. The Colloquium on Canine Melanoma was an online event held in December 2020, and had around 200 participants.
Author contributions
CF-A, ÊF, CO, BS, WF, ND, NO, SC, JC, MR, CB, MT, DA, and SF: writing and editing the manuscript. AB and LB: mentoring and editing the manuscript. MLZD: mentoring, writing, and editing the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
MulliganRM. Neoplastic diseases of dogs; neoplasms of melanin-forming cells. Am J Pathol. (1949) 25:339–55.
2.
PovarMLPOVARR. Malignant melanoma of the oral mucosa in a dog. J Am Vet Med Assoc. (1950) 117:223–4.
3.
BergmanPSmedleyR. Consensus on the Diagnosis of and Histopathologic Prognostication for Canine Melanocytic Neoplasms. Oncology-pathology working group (2020). Available online at: http://vetcancersociety.org/wp-content/uploads/2020/11/Melanoma-Consensus-Final_10AUG2020.pdf
4.
TeixeiraTFGentileLBda SilvaTCMennecierGChaibleLMCogliatiBet al. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas. Vet Res Commun. (2014) 38:29–38. 10.1007/s11259-013-9580-z
5.
HitteCLe BéguecCCadieuEWucherVPrimotAProuteauAet al. Genome-wide analysis of Long Non-Coding RNA profiles in canine oral melanomas. Genes. (2019) 10:477. 10.3390/genes10060477
6.
RahmanMMLaiYCHusnaAAChenHWTanakaYKawaguchiHet al. Transcriptome analysis of dog oral melanoma and its oncogenic analogy with human melanoma. Oncol Rep. (2020) 43:16–30. 10.3892/or.2019.7391
7.
RahmanMMLaiYCHusnaAAChenHWTanakaYKawaguchiHet al. Micro RNA transcriptome profile in canine oral melanoma. Int J Mol Sci. (2019) 20:4832. 10.3390/ijms20194832
8.
BroccaGFerraressoSZamboniCMartinez-MerloEMFerroSGoldschmidtMHet al. Array comparative genomic hybridization analysis reveals significantly enriched pathways in canine oral melanoma. Front Oncol. (2019) 9:1397. 10.3389/fonc.2019.01397
9.
WongKvan der WeydenLSchottCRFooteAConstantino-CasasFSmithSet al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat Commun. (2019) 10:353. 10.1038/s41467-018-08081-1
10.
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. (2015) 161:1681–96. 10.1016/j.cell.2015.05.044
11.
ChenEYTanCMKouYDuanQWangZMeirellesGVet al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. (2013) 14:128. 10.1186/1471-2105-14-128
12.
KuleshovMVJonesMRRouillardADFernandezNFDuanQWangZet al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. (2016) 44:W90–7. 10.1093/nar/gkw377
13.
FishilevichSNudelRRappaportNHadarRPlaschkesIIny SteinTet al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database. (2017) 2017:bax028. 10.1093/database/bax028
14.
GillardMCadieuEDe BritoCAbadieJVergierBDevauchellePet al. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell Melanoma Res. (2014) 27:90–102. 10.1111/pcmr.12170
15.
van der WeydenLBrennTPattonEEWoodGAAdamsDJ. Spontaneously occurring melanoma in animals and their relevance to human melanoma. J Pathol. (2020) 252:4–21. 10.1002/path.5505
16.
SmithSHGoldschmidtMHMcManusPM. A comparative review of melanocytic neoplasms. Vet Pathol. (2002) 39:651–78. 10.1354/vp.39-6-651
17.
SmedleyRCSpanglerWLEsplinDGKitchellBEBergmanPJHoHYet al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Vet Pathol. (2011) 48:54–72. 10.1177/0300985810390717
18.
BerginILSmedleyRCEsplinDGSpanglerWLKiupelM. Prognostic evaluation of Ki67 threshold value in canine oral melanoma. Vet Pathol. (2011) 48:41–53. 10.1177/0300985810388947
19.
VelosoESGonçalvesINNSilveiraTLOliveiraFSVieiraDSCassaliGDet al. Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas. BMC Vet Res. (2020) 16:24. 10.1186/s12917-020-2249-2
20.
VelosoESGonçalvesINNSilveiraTLEspirito SantoJTFigueiredoLVVaraschinMSet al. ZEB and Snail expression indicates epithelial-mesenchymal transition in canine melanoma. Res Vet Sci. (2020) 131:7–14. 10.1016/j.rvsc.2020.04.007
21.
SilveiraTLVelosoESGonçalvesINNCostaRFRodriguesMACassaliGDet al. Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas. Vet Comp Oncol. (2020) 18:727–38. 10.1111/vco.12601
22.
ProuteauAAndréC. Canine melanomas as models for human melanomas: clinical, histological, and genetic comparison. Genes. (2019) 10:501. 10.3390/genes10070501
23.
BostonSELuXCulpWTNMontinaroVRomanelliGDudleyRMet al. Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001-2012). J Am Vet Med Assoc. (2014) 245:401–7. 10.2460/javma.245.4.401
24.
WobeserBKKidneyBAPowersBEWithrowSJMayerMNSpinatoMTet al. Diagnoses and clinical outcomes associated with surgically amputated canine digits submitted to multiple veterinary diagnostic laboratories. Vet Pathol. (2007) 44:355–61. 10.1354/vp.44-3-355
25.
LiptakJMWithrowSJ. Cancer of gastrointestinal tract. In: WithrowSJVailDMPageRL, editors. Oncologia Clínica de Pequenos Animais. Vol. 5 ed. St. Louis, MO: Elsevier Saunders (2013). p. 381–95.
26.
TuohyJLSelmicLEWorleyDREhrhartNPWithrowSJ. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998-2011). J Am Vet Med Assoc. (2014) 245:1266–73. 10.2460/javma.245.11.1266
27.
SmithMM. Surgical approach for lymph node staging of oral and maxillofacial neoplasms in dogs. J Am Anim Hosp Assoc. (1995) 31:514–8. 10.5326/15473317-31-6-514
28.
SuamiHYamashitaSSoto-MirandaMAChangDW. Lymphatic territories. (Lymphosomes) in a canine: an animal model for investigation of postoperative lymphatic alterations. PLoS ONE. (2013) 8:e69222. 10.1371/journal.pone.0069222
29.
HerringESSmithMMRobertsonJL. Lymph Node Staging of Oral and Maxillofacial Neoplasms in 31 Dogs and Cats. J Vet Dent. (2002) 19:122–6. 10.1177/089875640201900301
30.
BeerPPozziARohrer BleyCBaconNPfammatterNSVenzinC. The role of sentinel lymph node mapping in small animal veterinary medicine: a comparison with current approaches in human medicine. Vet Comp Oncol. (2018) 16:178–87. 10.1111/vco.12372
31.
WilliamsLEPackerRA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). J Am Vet Med Assoc. (2003) 222:1234–6. 10.2460/javma.2003.222.1234
32.
BentzenSMOvergaardJThamesHDOvergaardMVejby HansenPvon der MaaseHet al. Clinical radiobiology of malignant melanoma. Radiother Oncol. (1989) 16:169–82. 10.1016/0167-8140(89)90017-0
33.
OvergaardJOvergaardMHansenPVvon der MaaseH. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol. (1986) 5:183–9210.1016/s0167-8140(86)80048-2
34.
BatemanKECattonPAPennockPWKruthSA. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med. (1994) 8:267–72. 10.1111/j.1939-1676.1994.tb03231.x
35.
FreemanKPHahnKAHarrisFDKingGK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). J Vet Intern Med. (2003) 17:96–101. 10.1892/0891-6640(2003)017<0096:todwom>2.3.co;2
36.
CanceddaSRohrer BleyCAresuLDacastoMLeoneVFPizzoniSet al. Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma. Vet Comp Oncol. (2016) 14:e146–57. 10.1111/vco.12122
37.
BlackwoodLDobsonMA. Radiotherapy of malignant melanomas in dogs. J Am Vet Med Assoc. (1996) 209:98–102.
38.
TheonAPRodrigueLCMadewellBR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc. (1997):210:778–84.
39.
CunhaSCSCorgozinhoKBSilvaFBFSilvaKVGCFerreiraAMR. Radiation therapy for oral melanoma in dogs: a retrospective study. Ciência Rural Santa Maria. (2018) 48:e20160396. 10.1590/0103-8478cr20160396
40.
LaroccaCALeBoeufNRSilkAWKaufmanHL. An update on the role of talimogene laherparepvec (T-VEC) in the treatment of melanoma: best practices and future directions. Am J Clin Dermatol. (2020) 21:821–32. 10.1007/s40257-020-00554-8
41.
SimonBUsluU. CAR-T cell therapy in melanoma: a future success story?Exp Dermatol. (2018) 27:1315–21. 10.1111/exd.13792
42.
BajgelmanMCStraussBE. Development of an adenoviral vector with robust expression driven by p53. Virology. (2008) 371:8–13. 10.1016/j.virol.2007.11.015
43.
HungerAMedranoRFZanattaDBDel VallePRMerkelCASallesTAet al. Reestablishment of p53/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discov. (2017) 3:17017. 10.1038/cddiscovery.2017.17
44.
Giglia-MariGSarasinA. TP53 mutations in human skin cancers. Hum Mutat. (2003) 21:217–28. 10.1002/humu.10179
45.
MerkelCAda Silva SoaresRBde CarvalhoACZanattaDBBajgelmanMCFratiniPet al. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer. (2010) 10:316. 10.1186/1471-2407-10-316
46.
TakaokaAHayakawaSYanaiHStoiberDNegishiHKikuchiHet al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. (2003) 424:516–23. 10.1038/nature01850
47.
MedranoRFCataniJPRibeiroAHTomazSLMerkelCACostanzi-StraussEet al. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy. Cancer Immunol Immunother. (2016) 65:371–82. 10.1007/s00262-016-1807-8
48.
QinXQBeckhamCBrownJLLukashevMBarsoumJ. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther. (2001) 4:356–64. 10.1006/mthe.2001.0464
49.
DavidTIPCerqueiraOLDLanaMGMedranoRFVHungerAStraussBE. Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector. Sci Rep. (2020) 10:17893. 10.1038/s41598-020-74826-y
50.
CerqueiraOLDClavijo-SalomonMACardosoECCitrangulo Tortelli JuniorTMendonçaSABarbutoJAMet al. Combined p14ARF and interferon-beta gene transfer to the human melanoma cell line SK-MEL-147 promotes oncolysis and immune activation. Front Immunol. (2020) 11:576658. 10.3389/fimmu.2020.576658
51.
SilvaGRO. [Establishment of Canine Melanoma Cell Lines and Transduction with Improved Adenoviral Vectors]. São Paulo, SP: University of São Paulo (2019).
52.
ColeyWB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. (1893) 105:487–510. 10.1097/00000441-189305000-00001
53.
AlmelaRMAnsónA. A review of immunotherapeutic strategies in canine malignant melanoma. Vet Sci. (2019) 6:15. 10.3390/vetsci6010015
54.
VentolaCL. Cancer immunotherapy, Part 3: challenges and future trends. P T. (2017) 42:514–21.
55.
EscorsD. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci. (2014) 2014:734515. 10.1155/2014/734515
56.
RolinskiJHusI. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy. J Immunotoxicol. (2014) 11:311–8. 10.3109/1547691X.2013.865094
57.
SanmamedMFChenL. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. (2018) 175:313–26. 10.1016/j.cell.2018.09.035
58.
VergantiSBerlatoDBlackwoodLAmores-FusterIPoltonGAEldersRet al. Use of oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract. (2017) 58:10–6. 10.1111/jsap.12613
59.
BöckelmannPKTizzianiSHSDuránNFávaroWJ. New therapeutic perspective for bladder cancer in dogs: toxicological and clinical effects of OncoTherad nanostructured immunotherapy. J Phys Conf Ser. (2019) 1323:012022. 10.1088/1742-6596/1323/1/012022
60.
DuránNDiasQCFávaroWJ. OncoTherad: a new nanobiological response modifier, its toxicological and anticancer activities. J Phys.: Conf Ser. (2019) 1323:012018. 10.1088/1742-6596/1323/1/012018
61.
NameJJVasconcelosARSouzaACRFávaroWJ. Vitamin D, zinc and glutamine: synergistic action with OncoTherad immunomodulator in interferon signaling and COVID-19 (review). Int J Mol Med. (2021) 47:11. 10.3892/ijmm.2021.4844
62.
AlonsoJCCReisIBGonçalvesJMSasakiBRdSCintraAADuranNet al. OncoTherad immunotherapy elicits promising responses in Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer: results from phase I/II study. J Clin Oncol. (2020) 38(Suppl. 15):e17048. 10.1200/JCO.2020.38.15_suppl.e17048
63.
FávaroWJIantasSRGonçalvesJMDiasQCReisIBBillisAet al. Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK/RANKL signaling: new therapeutic perspective for non-muscle invasive bladder cancer. J Clin Oncol. (2019) 37(Suppl. 15):e16004. 10.1200/JCO.2019.37.15_suppl.e16004
64.
MirLMOrlowskiS. Mechanisms of electrochemotherapy. Adv Drug Deliv Rev. (1999) 35:107–18. 10.1016/S0169-409X(98)00066-0
65.
CemazarMTamzaliYSersaGTozonNMirLMMiklavcicDet al. Electrochemotherapy in veterinary oncology. J Vet Intern Med. (2008) 22:826–31. 10.1111/j.1939-1676.2008.0117.x
66.
EdhemovicIBreceljEGasljevicGMarolt MusicMGorjupVMaliBet al. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol. (2014) 110:320–7. 10.1002/jso.23625
67.
CampanaLGGaluppoSMarconatoRMatthiessenLW. Electrochemotherapy for breast cancer. In: MiklavčičD, editor. Handbook of Electroporation. Cham: Springer (2017). 10.1007/978-3-319-32886-7_126
68.
EdhemovicIGadzijevEMBreceljEMiklavcicDKosBZupanicAet al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat. (2011) 10:475–85. 10.7785/tcrt.2012.500224
69.
MatthiessenLWKeshtgarMCuratoloPKunteCGrischkeEMOdiliJet al. Electrochemotherapy for breast cancer-results from the INSPECT database. Clin Breast Cancer. (2018) 18:e909–17. 10.1016/j.clbc.2018.03.007
70.
SuzukiDOHAnselmoJde OliveiraKDFreytagJORangelMMMarquesJLet al. Numerical model of dog mast cell tumor treated by electrochemotherapy. Artif Organs. (2015) 39:192–7. 10.1111/aor.12333
71.
TafutoSvon ArxCDe DivitiisCMauraCTPalaiaRAlbinoVet al. Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases. Int J Surg. (2015) 21(Suppl. 1):S78–82. 10.1016/j.ijsu.2015.04.095
72.
TozonNKodreVSersaGCemazarM. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res. (2005) 25:839–45.
73.
CampanaLGTestoriAMozzilloNRossiCR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol. (2014) 109:301–7. 10.1002/jso.23512
74.
GlassLFFenskeNAJaroszeskiMPerrottRHarveyDTReintgenDSet al. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol. (1996) 34:82–6. 10.1016/S0190-9622(96)90838-5
75.
TamzaliYBordeLRolsMPGolzioMLyazrhiFTeissieJ. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. Equine Vet J. (2012) 44:214–20. 10.1111/j.2042-3306.2011.00425.x
76.
WichtowskiMMurawaD. Electrochemotherapy in the treatment of melanoma. Contemp Oncol. (2018) 22:8–13. 10.5114/wo.2018.74387
77.
MiklavčičDMaliBKosBHellerRSeršaG. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online. (2014) 13:29. 10.1186/1475-925X-13-29
78.
MaliBJarmTSnojMSersaGMiklavcicD. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. (2013) 39:4–16. 10.1016/j.ejso.2012.08.016
79.
ProbstUFuhrmannIBeyerLWiggermannP. Electrochemotherapy as a new modality in interventional oncology: a review. Technol Cancer Res Treat. (2018) 17:1533033818785329. 10.1177/1533033818785329
80.
GehlJSersaGMatthiessenLWMuirTSodenDOcchiniAet al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol. (2018) 57:874–82. 10.1080/0284186X.2018.1454602
81.
TelladoMNMagliettiFHMichinskiSDMarshallGRSignoriE. Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome. Radiol Oncol. (2020) 54:68–78. 10.2478/raon-2020-0014
82.
MirLM. Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl. (2006) 4:38–44. 10.1016/j.ejcsup.2006.08.005
83.
SpugniniEPBaldiA. Electrochemotherapy in veterinary oncology state-of-the-art and perspectives. Vet Clin North Am Small Anim Pract. (2019) 49:967–79. 10.1016/j.cvsm.2019.04.006
84.
Dos AnjosDSBuenoCMagalhãesLFMagalhãesGMMattos-JuniorEPintoMMRet al. Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma. Sci Rep. (2019) 9:15819. 10.1038/s41598-019-52461-6
85.
Dos AnjosDSSierraORSpugniniEPDe NardiABFonseca-AlvesCE. Comparison of two different doses of bleomycin in electrochemotherapy protocols for feline cutaneous squamous cell carcinoma nonsegregated from ultraviolet light exposure. Sci Rep. (2020) 10:18362. 10.1038/s41598-020-75472-0 10. Vol. 18362
86.
Dos AnjosDSBuosiRGRorattoIMesquitaLDRMatizORSFonseca-AlvesCEet al. Preliminary assessment of electrochemotherapy feasibility in dogs with vesical transitional cell carcinoma. Vet Res Forum. (2020) 11:289–93. 10.30466/vrf.2020.113009.2688
87.
GehlJSkovsgaardTMirLM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs. (1998) 9:319–25. 10.1097/00001813-199804000-00005
88.
FrandsenSKVissingMGehlJ. A comprehensive review of calcium electroporation -A novel cancer treatment modality. Cancers. (2020) 12:290. 10.3390/cancers12020290
89.
Dos AnjosDSRodriguesCGSilvaNCDe NardiABFonseca-AlvesCE. Electrochemotherapy associated with calcium electroporation in metastatic feline cutaneous malignant melanoma. Acta Sci Vet. (2019) 47(Suppl. 1):435. 10.22456/1679-9216.96498
Summary
Keywords
oral melanoma, cutaneous melanoma, dog, melanocytic disorders, electrochemotherapy, radiation therapy, immunotherapy
Citation
Fonseca-Alves CE, Ferreira Ê, de Oliveira Massoco C, Strauss BE, Fávaro WJ, Durán N, Oyafuso da Cruz N, dos Santos Cunha SC, Castro JLC, Rangel MMM, Brunner CHM, Tellado M, dos Anjos DS, Fernandes SC, Barbosa de Nardi A, Biondi LR and Dagli MLZ (2021) Current Status of Canine Melanoma Diagnosis and Therapy: Report From a Colloquium on Canine Melanoma Organized by ABROVET (Brazilian Association of Veterinary Oncology). Front. Vet. Sci. 8:707025. doi: 10.3389/fvets.2021.707025
Received
08 May 2021
Accepted
19 July 2021
Published
16 August 2021
Volume
8 - 2021
Edited by
Laura Bongiovanni, Utrecht University, Netherlands
Reviewed by
Elena De Felice, University of Camerino, Italy
Updates
Copyright
© 2021 Fonseca-Alves, Ferreira, de Oliveira Massoco, Strauss, Fávaro, Durán, Oyafuso da Cruz, dos Santos Cunha, Castro, Rangel, Brunner, Tellado, dos Anjos, Fernandes, Barbosa de Nardi, Biondi and Dagli.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria Lucia Zaidan Dagli mlzdagli@usp.br
This article was submitted to Comparative and Clinical Medicine, a section of the journal Frontiers in Veterinary Science
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.